TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-9.4%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.21B
AUM Growth
-$432M
(-16%)
Cap. Flow
-$82.9M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
$15.1M |
| 2 |
Centene
CNC
|
$8.24M |
| 3 |
Moderna
MRNA
|
$7.61M |
| 4 |
Eli Lilly
LLY
|
$6.73M |
| 5 |
Sanofi
SNY
|
$6.15M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.8M |
| 2 |
Merck
MRK
|
$14.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
$10.3M |
| 4 |
Johnson & Johnson
JNJ
|
$10.2M |
| 5 |
Pfizer
PFE
|
$8.65M |
Sector Composition
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
101
DELISTED
bluebird bio
BLUE
| $3.87M | 0.18% |
6,500
-887
| -12% | -$528K |
|
102
Agilent Technologies
A
$36.5B
| $3.76M | 0.17% |
52,525
+25,200
| +92% | +$1.8M |
|
103
Fate Therapeutics
FATE
$116M
| $3.68M | 0.17% |
165,672
| – | – |
|
|
XLRN
104
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.65M | 0.17% |
40,606
-45,707
| -53% | -$4.11M |
|
105
Healthpeak Properties
DOC
$12.8B
| $3.59M | 0.16% |
150,392
+21,855
| +17% | +$521K |
|
106
Smith & Nephew
SNN
$16.5B
| $3.57M | 0.16% |
99,560
| – | – |
|
107
Ardelyx
ARDX
$1.57B
| $3.46M | 0.16% |
607,698
| – | – |
|
108
Amicus Therapeutics
FOLD
$2.46B
| $3.41M | 0.15% |
368,960
| – | – |
|
|
PVLA
109
Palvella Therapeutics, Inc. Common Stock
PVLA
$616M
| $3.3M | 0.15% |
18,116
| – | – |
|
110
CRISPR Therapeutics
CRSP
$4.99B
| $3.23M | 0.15% |
76,222
| – | – |
|
|
EPZM
111
DELISTED
Epizyme, Inc
EPZM
| $3.22M | 0.15% |
207,752
-145,350
| -41% | -$2.25M |
|
112
Takeda Pharmaceutical
TAK
$48.6B
| $3.19M | 0.14% |
210,146
| – | – |
|
113
Genmab
GMAB
$16.9B
| $3.14M | 0.14% |
148,148
+131,628
| +797% | +$2.79M |
|
|
HR
114
DELISTED
Healthcare Realty Trust Incorporated
HR
| $2.91M | 0.13% |
104,024
+20,395
| +24% | +$570K |
|
115
Revvity
RVTY
$10.1B
| $2.9M | 0.13% |
38,494
+19,483
| +102% | +$1.47M |
|
116
Rocket Pharmaceuticals
RCKT
$354M
| $2.9M | 0.13% |
207,555
| – | – |
|
|
ALLK
117
DELISTED
Allakos
ALLK
| $2.87M | 0.13% |
64,397
-6,999
| -10% | -$311K |
|
|
SAGE
118
DELISTED
Sage Therapeutics
SAGE
| $2.76M | 0.12% |
96,211
| – | – |
|
119
Inogen
INGN
$219M
| $2.66M | 0.12% |
51,406
| – | – |
|
120
ResMed
RMD
$40.6B
| $2.63M | 0.12% |
17,831
-9,944
| -36% | -$1.46M |
|
121
Editas Medicine
EDIT
$248M
| $2.58M | 0.12% |
130,201
-17,738
| -12% | -$352K |
|
|
DCPH
122
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $2.53M | 0.11% |
61,370
| – | – |
|
|
MNTA
123
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2.48M | 0.11% |
+91,316
| New | +$2.48M |
|
124
Alkermes
ALKS
$4.94B
| $2.45M | 0.11% |
169,930
-28,118
| -14% | -$405K |
|
|
AMRN
125
Amarin Corp
AMRN
$317M
| $2.42M | 0.11% |
30,190
+9,784
| +48% | +$783K |
|